Skip to main content

Table 1 Demographic and clinical characteristics of study population

From: Identification of genetic factors underlying persistent pulmonary hypertension of newborns in a cohort of Chinese neonates

Characteristics

All PPHN

(n = 115)

Preterm (< 34 weeks) PPHN

(n = 41)

Late preterm and term (≥34 weeks) PPHN

(n = 74)

P value (< 34 weeks PPHN vs ≥34 weeks PPHN)

Non-PPHN

(n = 115)

P value (≥34 weeks PPHN vs non-PPHN)

Baseline characteristics

 Male gender, n(%)

64 (55.7)

24 (58.5)

40 (54.1)

0.6430

62 (53.9)

0.9849

 Birth weight (g), mean(±SD)

2516.2 ± 1006.2

1358.8 ± 391.7

3157.4 ± 572.6

< 0.001

3169.3 ± 576.6

0.8896

 Gestational age (weeks), mean(±SD)

34.9 ± 4.4

29.7 ± 2.3

37.8 ± 1.9

< 0.001

38.2 ± 1.4

0.1649

 Premature (< 37 weeks), n(%)

60 (52.2)

41 (100)

19 (25.7)

< 0.001

17 (14.8)

0.0627

 Caesarean, n(%)

76 (66.1)

24 (58.5)

52 (70.3)

0.2030

70 (60.9)

0.1873

Primary diagnosis for PPHN cases

 Respiratory distress syndrome, n(%)

53 (46.1)

27 (65.9)

26 (35.1)

0.0015

/

/

 Meconium aspiration syndrome, n(%)

10 (8.7)

0 (0)

10 (13.5)

0.0135

/

/

 Pneumothorax, n(%)

17 (14.8)

3 (7.3)

14 (18.9)

0.0932

/

/

 Pneumonia, n(%)

44 (38.3)

14 (34.1)

30 (40.5)

0.4992

/

/

 Bronchopulmonary dysplasia, n(%)

10 (8.7)

9 (22.0)

1 (1.4)

0.0004

/

/

Treatment and prognosis for PPHN cases

 Ventilation time (days), mean(±SD)

12.7 ± 18.9

22.2 ± 26.9

6.8 ± 6.7

0.0015

/

/

 iNO, n(%)

17 (14.8)

1 (2.4)

16 (21.6)

0.0055

/

/

 Vasoactive agents therapy, n(%)

64 (55.7)

19 (46.3)

45 (60.8)

0.1347

/

/

 ECMO, n(%)

4 (3.5)

0 (0)

4 (5.4)

0.2952

/

/

 Mortality, n(%)

14 (12.2)

7 (17.1)

7 (9.5)

0.2474

/

/

  1. iNO Inhaled nitric oxide, ECMO Extracorporeal membrane oxygenation